Hardman TC - Search Results

1

Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers.

Falcoz C, Jenkins JM, Bye C, Hardman TC, Kenney KB, Studenberg S, Fuder H, Prince WT. Falcoz C, et al. Among authors: hardman tc. J Clin Pharmacol. 2002 Aug;42(8):887-98. doi: 10.1177/009127002401102803. J Clin Pharmacol. 2002. PMID: 12162471 Clinical Trial.

2

Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.

Moore KH, Cass LM, Dallow N, Hardman TC, Jones A, Boyce M, Prince WT. Moore KH, et al. Among authors: hardman tc. Eur J Clin Pharmacol. 2001 Jan-Feb;56(11):805-11. doi: 10.1007/s002280000224. Eur J Clin Pharmacol. 2001. PMID: 11294370 Clinical Trial.

3

Pharmacokinetics and tolerability of GW420867X, a nonnucleoside reverse transcriptase inhibitor, following single escalating doses in healthy male volunteers.

Moore KH, Cass LM, Dallow N, Hardman TC, Jones A, Boyce M, Prince WT. Moore KH, et al. Among authors: hardman tc. J Clin Pharmacol. 2001 Oct;41(10):1098-105. doi: 10.1177/00912700122012706. J Clin Pharmacol. 2001. PMID: 11583478 Clinical Trial.

4

Future challenges for microsomal transport protein inhibitors.

Wierzbicki AS, Hardman T, Prince WT. Wierzbicki AS, et al. Curr Vasc Pharmacol. 2009 Jul;7(3):277-86. doi: 10.2174/157016109788340703. Curr Vasc Pharmacol. 2009. PMID: 19601852 Review.

5

New therapies to reduce low-density lipoprotein cholesterol.

Wierzbicki AS, Viljoen A, Hardman TC, Mikhailidis DP. Wierzbicki AS, et al. Among authors: hardman tc. Curr Opin Cardiol. 2013 Jul;28(4):452-7. doi: 10.1097/HCO.0b013e3283605fa2. Curr Opin Cardiol. 2013. PMID: 23736819 Review.

6

The apolipoprotein E2 allele modulates activity and maximal velocity of the sodium-lithium countertransporter.

Wierzbicki AS, Hardman TC, Cheung J, Lambert-Hammill M, Patel S, Morrish Z, Lumb PJ, Lant AF. Wierzbicki AS, et al. Among authors: hardman tc. Am J Hypertens. 2002 Jul;15(7 Pt 1):633-7. doi: 10.1016/s0895-7061(02)02927-8. Am J Hypertens. 2002. PMID: 12118912

7

HIV lipodystrophy and its metabolic consequences: implications for clinical practice.

Wierzbicki AS, Purdon SD, Hardman TC, Kulasegaram R, Peters BS. Wierzbicki AS, et al. Among authors: hardman tc. Curr Med Res Opin. 2008 Mar;24(3):609-24. doi: 10.1185/030079908X272742. Curr Med Res Opin. 2008. PMID: 18208641 Review.

8

Sodium-glucose co-transporter 2 inhibitors: from apple tree to 'Sweet Pee'.

Hardman TC, Rutherford P, Dubrey SW, Wierzbicki AS. Hardman TC, et al. Curr Pharm Des. 2010;16(34):3830-8. doi: 10.2174/138161210794455111. Curr Pharm Des. 2010. PMID: 21128897 Review.

9

Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia.

Wierzbicki AS, Hardman TC, Viljoen A. Wierzbicki AS, et al. Among authors: hardman tc. Expert Opin Investig Drugs. 2012 May;21(5):667-76. doi: 10.1517/13543784.2012.679340. Expert Opin Investig Drugs. 2012. PMID: 22493980 Review.

10

Relation between sodium-lithium countertransport and hypertriglyceridemia in type V hyperlipidemia.

Wierzbicki AS, Hardman TC, Cheung J, Patel M, Smallberger S, Lumb PJ, Lant AF. Wierzbicki AS, et al. Among authors: hardman tc. Am J Hypertens. 2001 Jan;14(1):32-7. doi: 10.1016/s0895-7061(00)01228-0. Am J Hypertens. 2001. PMID: 11206676

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

67 results

Search Page

Filters